CytomX Therapeutics, Inc. news
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ET.
A live webcast of the presentation will be available on the Events and Presentations page o
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 (NCT05387265). CX-904 is a conditionally activated T-cell-engaging bispecific (T
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022.
Dr. Scarlett has served as a member of the
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Frederick W. Gluck is retiring from its board of directors, effective June 30th, 2022.
“It has been an honor to serve on the CytomX board since the company’s founding,” said Frederick W. Gluck. “With a deep and differentiated clinical pipel
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a virtual panel discussion at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 12:50 p.m. ET.
A live webcast of the panel wil